drugset
drugset / Trial / NCT06904300

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

NCT06904300 ↗

Phase 2 Not yet recruiting 110 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

A Randomized, Controlled, Multi-center Phase II Study of Ivonescimab (AK112) plus Paclitaxel versus Paclitaxel with or without Ramucirumab as second-line therapy in subjects with advanced gastric or gastroesophageal junction（G/GEJ）cancer who failed immunochemotherapy

Timeline

Start
2025-08-15
Primary completion
2028-04-30
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody 20 mg/kg Intravenous
Comparator Ramucirumab Monoclonal antibody 8 mg/kg Intravenous
Background Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications

gastric cancer